• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases
      • All News Releases
      • All Public Company
      • English-only


      • News Releases Overview
      • Multimedia Gallery
      • All Multimedia
      • All Photos
      • All Videos


      • Multimedia Gallery Overview
      • Trending Topics
      • All Trending Topics


  • Business & Money
      • Auto & Transportation
      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation


      • Auto & Transportation Overview
      • Business Technology
      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors


      • Business Technology Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television


      • Entertain­ment & Media Overview
      • Financial Services & Investing
      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Stock Offering
      • Stock Split
      • Venture Capital


      • Financial Services & Investing Overview
      • General Business
      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News


      • General Business Overview
  • Science & Tech
      • Consumer Technology
      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications


      • Consumer Technology Overview
      • Energy & Natural Resources
      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities


      • Energy & Natural Resources Overview
      • Environ­ment
      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters


      • Environ­ment Overview
      • Heavy Industry & Manufacturing
      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco


      • Heavy Industry & Manufacturing Overview
      • Telecomm­unications
      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications


      • Telecomm­unications Overview
  • Lifestyle & Health
      • Consumer Products & Retail
      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys


      • Consumer Products & Retail Overview
      • Entertain­ment & Media
      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television


      • Entertain­ment & Media Overview
      • Health
      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine


      • Health Overview
      • Sports
      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories


      • Sports Overview
      • Travel
      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry


      • Travel Overview
  • Policy & Public Interest
      • Policy & Public Interest
      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy


      • Policy & Public Interest Overview
  • People & Culture
      • People & Culture
      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women


      • People & Culture Overview
      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO

      Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Policy & Public Interest
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • People & Culture
    • People & Culture
    • Send a Release
    • Sign Up
    • Log In
    • Resources
    • Blog
    • Journalists
    • RSS
    • GDPR
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

Doctor Develops New Method to Significantly Reduce Cost and Improve Effectiveness of Cancer Treatment

Immunotherapy drugs such as Yervoy, Optdivo and Keytruda are injected directly into the tumor after image-guided cryoablation


News provided by

Image Guided Cancer Specialist

Oct 13, 2016, 08:30 ET

Share this article

Share this article


MEXICO CITY, Oct. 13, 2016 /PRNewswire/ -- Image Guided Cancer Specialist Medical doctor, board-certified radiologist and researcher Jason Williams, MD, has a new solution to the spiraling costs of cancer treatments: Inject the immunotherapy drugs directly into the cancerous tumor after using image-guided cryoablation.

Continue Reading
Cryoablation combined with immunotherapy enhances the anti-cancer immune response
Cryoablation combined with immunotherapy enhances the anti-cancer immune response
Cryoablation Immunotherapy
Cryoablation Immunotherapy

Approved immunotherapy drugs (such as Yervoy, Keytruda and Optdivo) are proving highly effective at manipulating the body's immune system to fight cancer. When cancer develops, the tumor's cells put a brake on the immune system, stopping normal immune reactions to protect the invading cancer cells. The current class of immunotherapy drugs flips the switch back, so that the immune system can function normally.

However, these drugs are also extremely expensive. The average cost for using these drugs in combination at a standard dose is about $300,000 per year. And the higher doses being used in the current research mean that figure could climb to $1 million annually. At the American Society of Clinical Oncology Annual Meeting last year, Leonard Saltz, MD, from Memorial Sloan Kettering Cancer Center in New York, said the total cost to treat all metastatic cancer patients in the United States would be an "unsustainable" $174 billion per year. Other issues are that these drugs can potentially provoke an autoimmune disease response; by taking off the brake, the immune system can go into overdrive and begin attacking normal cells.

That's because they are administered intravenously and, therefore, throughout the body. Dr. Williams wants to take the benefits of immunotherapy drugs and enhance them with better precision. Indeed, injection of immunotherapy is very promising (see "Further reading"). Animal research has shown that combining injection of immunotherapy drugs with cryoablation of the tumor improves survival rates by more than 80%. The ablation process kills the tumor inside the body, releasing tumor antigens to stimulate an anti-cancer immune response. However, this immune stimulation is rarely strong enough on its own to generate a curative response — until you add immune checkpoint-inhibitor drugs.

"Biologically, the idea makes sense, because intentionally leaving dead tissue for the body to dispose of naturally is a way to potentially immunize against cancer cells," says tumor immunology and immunotherapy researcher Alex Y. Huang, MD, PhD, associate professor of the department of pediatrics at Case Western Reserve University School of Medicine, and clinical fellowship director of the division of pediatric hematology/oncology at University Hospitals Case Medical Center/Rainbow Babies & Children's Hospital. "Cryoablation uses cold temperature to induce necrotic cell death, which is a signal for the immune system to wake up. The dead tumor proteins will be seen as foreign by the immune system, which will attack the cancer."

Dr. Williams's model is novel because after freezing and killing those cells, he then uses image guidance technology to put probes into the remaining tumor. Then, instead of surgically removing the cancerous growth, he injects the immunotherapy drugs directly into the problematic tissue.

"This has the double benefit of activating the local immune system against cancer in other locations, without globally activating the immune system against the patient's healthy tissue," says Dr. Huang. "The risk of hitting the wrong tissue is low and, we know these drugs are safe at much higher systemic rather than smaller, targeted doses. The potential for systemic toxicity is lower and, because the drugs are given only locally, the cost is vastly reduced."

Animal-model studies have shown that one-eighth the typical IV dose is required when using local injections. If the current therapy costs $300,000 per year, the same clinical effectiveness could be achieved for $37,500 worth of drug.

Dr. Williams has already used this therapy in approximately 80 human patients, including one patient with advanced breast cancer who had more than 30 tumors in the lungs, bones and brain.

"A single treatment ablated two lung tumors and, using combination immunotherapy, she had complete resolution of the tumors in the body and 50% reduction in size and number of the brain tumors," says Dr. Williams.  In many patients, we have seen complete resolution of their cancer, even in remote sites not directly treated.  We have treated enough patients now to know that these results are not a fluke, but I look forward to testing this therapy in an official clinical trial."

Dr. Huang notes that clinical trials are needed to prove the technique, and further research would be needed to develop protocols for patient selection and reproducibly safe, effective use of the combined cryoablation/immunotherapy-injection technique. Dr. Williams hopes to get funding and approval for further trials, so that he can prove his results in a controlled setting.

"The combination offers equal effectiveness, reduced cost and lower toxicity — it's a win all the way around," says Dr. Williams. "I think with a little tweaking of the therapy, and we could be truly talking about a 'cure,' in a very high percentage of patients," says Dr. Williams.

Further reading

  1. Chustecka Z (2015). Full text available at: http://www.medscape.com/viewarticle/845707#vp_1
  2. Fransen MF, van der Sluis TC, Ossendorp F, et al (2013). Full text: http://clincancerres.aacrjournals.org/content/19/19/5381.long
  3. Marabelle A, Kohrt H, Levy R. Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817012/
  4. Nierkens S, den Brok MH, Sutmuller RPM, et al. Full text: http://cancerres.aacrjournals.org/content/68/13/5390.long
  5. Nierkens S, den Brok MH, Garcia G, et al. Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653311/
  6. Waltz R, Solomon SB, Petre EN, et al. Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4526218/

Contact: Jason R. Williams, MD
T: 844-359-4201
E: Email
Web: www.cancerablation.com

Photo - http://photos.prnewswire.com/prnh/20161012/427820  
Photo - http://photos.prnewswire.com/prnh/20161012/427821

SOURCE Image Guided Cancer Specialist

Related Links

http://www.cancerablation.com

Modal title

    Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

    Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

    About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement

    • Asia
    • Brazil
    • Canada
    • Czech
    • Denmark
    • Finland
    • France
    • Germany
    • India
    • Israel
    • Italy
    • Mexico
    • Middle East
    • Netherlands
    • Norway
    • Poland
    • Portugal
    • Russia
    • Slovakia
    • Spain
    • Sweden
    • United Kingdom

    My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision


Products


About


My Services
  • All News Releases
  • Online Member Center
  • ProfNet℠
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2021 Cision US Inc.